Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05546879 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

Study acronym: Liver-NET1
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Suspended to Active, Not Recruitingv9 Show 4 more changesShow less
    • Study completion pushed from Mar 15, 2027 to Mar 19, 2029
    • Study sites: 1 to 9
    • Primary completion date changed from estimate of Mar 15, 2026 to Mar 19, 2026
    • Secondary endpoints: details revised at 4 of 9 entries
  2. Trial status: Recruiting to Suspended Sponsor's reason: Number of patients achieved and treatment ongoing
    • Enrollment target: estimated 52 to confirmed 43
    • Secondary endpoints: 2 to 9
    • Site details revised
    v8
  3. Primary completion date: Nov 15, 2024 to Mar 15, 2026
    • Study completion date: Nov 15, 2025 to Mar 15, 2027
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints: 1 to 2
    v7
  4. Re-verified, no change to tracked fieldsv6
  5. Eligibility criteria expanded, about 186 words
    • Study title shortened, about 1 word
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Start date changed from estimate of Nov 2022 to Mar 15, 2023
    • Study sites: 0 to 1
    • Primary completion date: Nov 2024 to Nov 15, 2024
    • Study completion date: Nov 2024 to Nov 15, 2025
  2. Re-verified, no change to tracked fieldsv3
  3. Study title shortened, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in first line setting in patients with unresectable hepatocellular carcinoma. The study drug which is tested is the NP137 in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.
Trial Details
NCT Number NCT05546879
Lead Sponsor University Hospital, Grenoble
Collaborators: NETRIS Pharma
Conditions
(from sponsor)		 Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov